Mallet Luc, Polosan Mircea, Jaafari Nematollah, Baup Nicolas, Welter Marie-Laure, Fontaine Denys, du Montcel Sophie Tezenas, Yelnik Jérôme, Chéreau Isabelle, Arbus Christophe, Raoul Sylvie, Aouizerate Bruno, Damier Philippe, Chabardès Stephan, Czernecki Virginie, Ardouin Claire, Krebs Marie-Odile, Bardinet Eric, Chaynes Patrick, Burbaud Pierre, Cornu Philippe, Derost Philippe, Bougerol Thierry, Bataille Benoit, Mattei Vianney, Dormont Didier, Devaux Bertrand, Vérin Marc, Houeto Jean-Luc, Pollak Pierre, Benabid Alim-Louis, Agid Yves, Krack Paul, Millet Bruno, Pelissolo Antoine
The authors' affiliations are listed in the Appendix.
N Engl J Med. 2008 Nov 13;359(20):2121-34. doi: 10.1056/NEJMoa0708514.
Severe, refractory obsessive-compulsive disorder (OCD) is a disabling condition. Stimulation of the subthalamic nucleus, a procedure that is already validated for the treatment of movement disorders, has been proposed as a therapeutic option.
In this 10-month, crossover, double-blind, multicenter study assessing the efficacy and safety of stimulation of the subthalamic nucleus, we randomly assigned eight patients with highly refractory OCD to undergo active stimulation of the subthalamic nucleus followed by sham stimulation and eight to undergo sham stimulation followed by active stimulation. The primary outcome measure was the severity of OCD, as assessed by the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), at the end of two 3-month periods. General psychopathologic findings, functioning, and tolerance were assessed with the use of standardized psychiatric scales, the Global Assessment of Functioning (GAF) scale, and neuropsychological tests.
After active stimulation of the subthalamic nucleus, the Y-BOCS score (on a scale from 0 to 40, with lower scores indicating less severe symptoms) was significantly lower than the score after sham stimulation (mean [+/-SD], 19+/-8 vs. 28+/-7; P=0.01), and the GAF score (on a scale from 1 to 90, with higher scores indicating higher levels of functioning) was significantly higher (56+/-14 vs. 43+/-8, P=0.005). The ratings of neuropsychological measures, depression, and anxiety were not modified by stimulation. There were 15 serious adverse events overall, including 1 intracerebral hemorrhage and 2 infections; there were also 23 nonserious adverse events.
These preliminary findings suggest that stimulation of the subthalamic nucleus may reduce the symptoms of severe forms of OCD but is associated with a substantial risk of serious adverse events. (ClinicalTrials.gov number, NCT00169377.)
重度难治性强迫症(OCD)是一种致残性疾病。丘脑底核刺激术已被证实可用于治疗运动障碍,有人提出将其作为一种治疗选择。
在这项为期10个月的交叉、双盲、多中心研究中,评估丘脑底核刺激术的疗效和安全性,我们将8例高度难治性强迫症患者随机分为两组,一组先接受丘脑底核的主动刺激,然后接受假刺激;另一组先接受假刺激,然后接受主动刺激。主要结局指标是在两个3个月疗程结束时,通过耶鲁-布朗强迫症量表(Y-BOCS)评估的强迫症严重程度。使用标准化精神科量表、功能总体评定量表(GAF)和神经心理学测试评估一般精神病理学发现、功能和耐受性。
在丘脑底核接受主动刺激后,Y-BOCS评分(范围为0至40分,分数越低表明症状越轻)显著低于假刺激后的评分(均值[±标准差],19±8 vs. 28±7;P = 0.01),GAF评分(范围为1至90分,分数越高表明功能水平越高)显著更高(56±14 vs. 43±8,P = 0.005)。神经心理学测量、抑郁和焦虑的评分未因刺激而改变。总体共有15例严重不良事件,包括1例脑出血和2例感染;还有23例非严重不良事件。
这些初步研究结果表明,丘脑底核刺激术可能减轻重度强迫症的症状,但与严重不良事件的重大风险相关。(ClinicalTrials.gov编号,NCT00169377。)